Sales of Doliprane – paracetamol which can alleviate the fever and aches associated with the virus – shot up by more than 20%, helping boost the firm's net sales by 6.9% to nearly 9 billion euros ($9.6 billion).
"COVID-19 stocking in channels explains about half of company sales growth in Q1," the company said in a statement.
The company also credited sales of Dupixent, a treatment for atopic dermatitis and asthma, which soared by nearly 130%.
Sanofi said its net income grew by 15.9% over the first 3 months of 2020, with "roughly half of this growth due to COVID-19 impact."
Meanwhile, it has launched two studies into whether hydroxychloroquine, a drug for rheumatoid arthritis and lupus which Sanofi sells under the brand name Plaquenil, can be an effective treatment for coronavirus patients.
More than 190,000 people have died – including almost 22,000 in France – and nearly 2,700,000 been infected since the virus emerged in China in December. – Rappler.com